| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 17.39▲ | 17.35▲ | 17.44▲ | 17.18▲ | 17.63▼ |
| MA10 | 17.38▲ | 17.47▼ | 17.42▲ | 17.26▲ | 18.77▼ |
| MA20 | 17.36▲ | 17.30▲ | 17.07▲ | 17.90▼ | 22.22▼ |
| MA50 | 17.51▼ | 17.08▲ | 17.08▲ | 18.98▼ | 19.52▼ |
| MA100 | 17.22▲ | 17.08▲ | 17.85▼ | 22.39▼ | 26.95▼ |
| MA200 | 17.20▲ | 17.94▼ | 18.17▼ | 20.83▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.014▲ | -0.014▼ | 0.055▲ | 0.006▲ | -0.636▼ |
| RSI | 53.293▲ | 55.390▲ | 54.902▲ | 45.232▼ | 42.353▼ |
| STOCH | 60.079 | 22.264 | 63.494 | 35.124 | 16.825▼ |
| WILL %R | -14.286▲ | -52.525 | -36.749 | -67.849 | -90.988▼ |
| CCI | 100.859▲ | -19.436 | 41.733 | -22.497 | -107.825▼ |
|
Saturday, February 14, 2026 06:25 AM
Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/02/26 | 17.18 | 17.93 | 17.18 | 17.38 | 65,508 |
| 12/02/26 | 17.00 | 17.51 | 16.265 | 17.00 | 81,270 |
| 11/02/26 | 17.03 | 17.06 | 16.20 | 16.89 | 113,632 |
| 10/02/26 | 17.50 | 17.7199 | 16.93 | 17.00 | 86,945 |
| 09/02/26 | 17.28 | 17.95 | 16.50 | 17.62 | 77,873 |
| 06/02/26 | 16.87 | 17.46 | 16.30 | 17.23 | 91,235 |
| 05/02/26 | 17.18 | 17.58 | 15.93 | 16.37 | 213,704 |
| 04/02/26 | 17.82 | 18.37 | 16.65 | 17.18 | 139,245 |
| 03/02/26 | 18.15 | 18.91 | 16.80 | 17.56 | 114,441 |
| 02/02/26 | 17.45 | 18.95 | 17.00 | 18.33 | 129,967 |
|
|
||||
|
|
||||
|
|